GlaxoSmithKline (GSK) confirmed that it is to appeal against the decision by NICE to deny NHS funding for Tyverb® (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive).1 If successful the appeal will enable the NHS to offer a similar level of access to lapatinib as other EU countries.
More...